We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -72.00 | -0.66% | 10,842.00 | 10,840.00 | 10,844.00 | 10,934.00 | 10,764.00 | 10,914.00 | 411,168 | 14:05:15 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 28.23 | 168.13B |
From Apr 2019 to Apr 2024
LONDON--AstraZeneca PLC (AZN.LN) has entered into an agreement with Recordati S.p.A (REC.MI) for the commercial rights to AstraZeneca's heart-failure drug Seloken/Seloken ZOK and associated Logimax fixed-dose combination treatments in Europe.
AstraZeneca said Monday that Recordati will pay $300 million upon completion of the agreement. AstraZeneca will also receive sales-related income through tiered royalties, initially at a double-digit percentage of sales.
AstraZeneca said it will manufacture and supply the medicines to Recordati under a supply agreement.
-Write to Razak Musah Baba at razak.baba@wsj.com; Twitter: @Raztweet
(END) Dow Jones Newswires
May 22, 2017 02:31 ET (06:31 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
